iPS Cells for Modelling and Treatment of Retinal Diseases

Journal of Clinical Medicine

Fred K. Chen³  Samuel McLenachan³  Michael Edel¹  Lyndon Da Cruz²  Peter J. Coffey⁴  David A. Mackey³ 

[1] Control of Pluripotency Laboratory, Department of Physiological Sciences I, Faculty of Medicine, University of Barcelona, Hospital Clinic, Casanova 143, Barcelona 08036, Spain; E-Mail:;Department of Vitreoretinal Surgery, Moorfields Eye Hospital, London EC1V 2PD, UK; E-Mail:;Centre for Ophthalmology and Visual Science (Incorporating Lions Eye Institute), The University of Western Australia, Perth WA 6009, Australia; E-Mails:;Division of Cellular Therapy, Institute of Ophthalmology, University College of London, London EC1V 9EL, UK; E-Mail:

关键词: age-related macular degeneration;    inherited retinal disease;    retinal dystrophy;    macular dystrophy;    retina;    induced pluripotent;    stem cells;    cell transplantation;    disease modelling;    genetic diagnosis;   

DOI  :  10.3390/jcm3041511

来源: mdpi

【 摘 要 】

For many decades, we have relied on immortalised retinal cell lines, histology of enucleated human eyes, animal models, clinical observation, genetic studies and human clinical trials to learn more about the pathogenesis of retinal diseases and explore treatment options. The recent availability of patient-specific induced pluripotent stem cells (iPSC) for deriving retinal lineages has added a powerful alternative tool for discovering new disease-causing mutations, studying genotype-phenotype relationships, performing therapeutics-toxicity screening and developing personalised cell therapy. This review article provides a clinical perspective on the current and potential benefits of iPSC for managing the most common blinding diseases of the eye: inherited retinal diseases and age-related macular degeneration.

【 授权许可】

CC BY   
© 2014 by the authors; licensee MDPI, Basel, Switzerland.